Risk of breakthrough SARS‐CoV‐2 infection and clinical outcomes among vaccinated patients with type 2 diabetes
Main finding · Breakthrough infectionResult — go to the resultHazard ratio 1.10 95% CI 1.06–1.14Authors' conclusion
While patients with T2D remain a vulnerable population to SARS-CoV-2 infection even after full-vaccination, full-vaccination was associated with a lower risk of adverse clinical outcomes after SARS-CoV-2 infection. These findings support the guidelines recommending patients with T2D as a priority vaccination group.
Study context
- Population
- Patients with and without T2D, South Korea's linked nationwide COVID-19 registry and claims data, 2018–2021; age 63.5 years; 50.9% malePropensity-score (PS)-matched
- Participants
- 2,109,970 patients
- Exposure
- Fully vaccinated patients with vs without T2D (breakthrough infection); fully vaccinated vs unvaccinated T2D patients (severe outcomes)
- Outcome
- Breakthrough SARS-CoV-2 infection
Methodological details1:1 propensity-score matched, nationwide COVID-19 registry linked to claims data
- 1:1 propensity-score matched
- Nationwide COVID-19 registry linked to claims data
Main finding
Breakthrough infection
Hazard ratio
1.10
95% CI 1.06–1.14
T2Dvs Without T2D
HR 1.10 (95% CI 1.06–1.14)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Severe COVID-19 outcomes after SARS-CoV-2 infection (T2D cohort)Fully vaccinated T2Dvs Unvaccinated T2DAll-cause mortality | 0.54 (0.43–0.67) | |
| Severe COVID-19 outcomes after SARS-CoV-2 infection (T2D cohort)Fully vaccinated T2Dvs Unvaccinated T2DICU admission/MV use | 0.31 (0.23–0.41) | |
| Severe COVID-19 outcomes after SARS-CoV-2 infection (T2D cohort)Fully vaccinated T2Dvs Unvaccinated T2DHospitalization | 0.73 (0.68–0.78) | |
| 0.20.5125Hazard ratio (log scale) |
- Severe COVID-19 outcomes after SARS-CoV-2 infection (T2D cohort): 1:1 PS-matched
Breakthrough infection in T2D patients receiving insulin
- Increased risk of breakthrough infections more notable among T2D patients receiving insulin treatment
Original publication
Risk of breakthrough SARS‐CoV‐2 infection and clinical outcomes among vaccinated patients with type 2 diabetes. Diabetes Obes Metab. Published 13 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →